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Abstract 
Background and Purpose:  Using video-based directly observed therapy (VDOT) to remotely monitor 
tuberculosis (TB) patients’ treatment is now a viable option due to the advancement and expansion of 
technology. This study determined the utilization levels, benefits, barriers, and outcomes of California 
public health departments using VDOT to treat TB. Methods: Interviews (n=7) with pilot site staff in 
California and a survey (n=56) were used for data collection. In 2015 the survey was disseminated to 
attendees of the California Tuberculosis Control Association annual conference. Results: Almost 27 
percent (n=15) of survey respondents were using VDOT. Reported benefits were high and centered on 
patient and provider satisfaction, cost savings, and staff safety. The highest concern was reimbursement, 
specifically that California’s Medicaid program, Medi-Cal, reimburses for in-person DOT but not VDOT. 
Conclusion: VDOT is a practical and effective option for providing DOT as it has many benefits with 
minimal concerns. Reimbursement equal to that of in-person DOT and the continued technological 
improvements should alleviate the existing hindrances that are currently preventing many health 
departments from implementing VDOT or expanding their existing program. Satisfaction is high, 
outcomes are positive, and VDOT is cost effective so efforts should be made to break down the barriers to 
expansion.  
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Introduction 
 
The steady decline of tuberculosis (TB) cases in 
California seen over the last 25 years ended in 
2015. The number of TB cases and the TB rate 
were unchanged in 2015 (2,133 cases and a rate 
of 5.5 per 100,000 population) compared with 
2014 (California Department of Public Health, 
2016a).  
 
The Centers for Disease Control and Prevention 
(CDC) recommends the use of directly observed 
therapy (DOT) as the most effective way of 
administering medication in treating TB (CDC, 
2012). DOT consists of observing patients 
taking their medication to assure adherence to a 
course of treatment. Strict adherence to ingesting 
the medication is necessary, because patients 
who take their medications inconsistently or stop 
early are at risk for disease progression and 
death, transmission of the disease to others, and 
development of drug-resistant strains of the TB 
bacteria that are much more difficult and 
expensive to treat. 
 
While effective in treating TB, DOT is labor 
intensive and an expensive treatment approach 
that taxes limited public health resources 
(Belknap, Weis, Brookens, Au-Yeung, Moon, 
DiCarlo, & Reves, 2013). Treatment of TB can 
range from three months for latent infections of 
TB (CDC, 2014b) to 24 months for multi-drug 
resistant TB (MDR-TB) (National Institute of 
Allergy and Infectious Diseases, 2012), and the 
estimated cost of treating TB patients in 
California in 2015 is $72 million in direct 
medical costs alone to treat active TB disease 
(California Department of Public Health, 
2016b). The use of telehealth to administer DOT 
(Video Directly Observed Therapy [VDOT]) 
may prove to be an effective way to address the 
logistical and financial challenges faced by 
public health departments in using DOT, while 
still effectively treating TB patients. The Center 
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for Connected Health Policy (CCHP) and the 
University of California San Diego (UCSD) 
conducted a two-year statewide study in 
California. The study goal was to assess the 
acceptance and utilization levels, barriers and 
enabling factors, outcomes, and policy and legal 
provisions related to VDOT as well as other 
applications of the technology. Background 
information about VDOT as well as the study 
methods and findings are presented in this 
article. 
 
Background of VDOT 
VDOT is a form of telehealth that allows a 
healthcare worker (HCW) to remotely observe 
an infected individual taking his or her 
medications. California law defines telehealth 
as: 
“The mode of delivering health care services 
and public health via information and 
communication technologies to facilitate the 
diagnosis, consultation, treatment, education, 
care management, and self-management of a 
patient's health care while the patient is at the 
originating site and the health care provider is 
at a distant site. Telehealth facilitates patient 
self-management and caregiver support for 
patients and includes synchronous interactions 
and asynchronous store and forward transfers.” 
(California Legislative Information, 2012).  
 
Two modes of telehealth delivery may be used 
for VDOT: 
 
1. Real time (synchronous) VDOT (S-VDOT) 
allows the HCW to virtually observe the TB 
patient taking his or her medication using video 
transmission utilizing a device such as a mobile 
phone. Observation of the person taking the 
medication by the HCW occurs at the same time 
the event is happening. 
 
2. Store-and-forward (asynchronous) VDOT 
(A-VDOT) consists of the patient digitally 
recording the ingestion of the medication using 
technology, such as a mobile phone. The 
recorded video is transmitted to a secure server 
where it is stored for viewing by the HCW at a 
later time.  A summary of the features of both 
modalities is in Table 1.   
 
Table 1 
 
In-person DOT and VDOT Features 
 
 
 
In-Person Directly Observed 
Therapy (DOT) 
Synchronous Video Directly 
Observed Therapy 
(S-VDOT) 
Asynchronous Video 
Directly Observed Therapy 
(A-VDOT) 
Procedures Occurs in real-time 
(synchronous). 
HCW must be physically 
present to observe the patient 
ingesting medication. 
Occurs in real-time 
(synchronous). 
HCW virtually observes (via 
live-video) the patient 
ingesting medication. 
Does not occur in real-time 
(asynchronous). 
Patient records a video 
ingesting medication and sends 
it to HCW to observe at a later 
time. 
Requirements Requires patient and/or HCW 
to physically travel.  
Treatment regimen must fit to 
the patient and HCW’s 
schedules. 
Does not require technological 
equipment nor a cellular/ 
wireless fidelity (Wi-Fi) 
connection. 
 
Does not require patient and/or 
HCW to travel (if periodic 
physical check-ins are required 
then travel is significantly 
reduced). 
Treatment regimen must fit to 
the patient and HCW’s 
schedules. 
Requires technology, such as a 
smartphone, and a cellular/Wi-
Fi connection. 
Does not require patient and/or 
HCW to travel (if periodic 
physical check-ins are required 
then travel is significantly 
reduced). 
Treatment regimen fits to both 
patient and HCW’s schedule. 
Allows for monitoring on 
weekends and when patient is 
traveling. 
Requires technology, such as a 
smartphone, and a cellular/Wi-
Fi connection. 
HCW=Healthcare worker
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Little research exists on VDOT and what does 
exist uses antiquated technology or telephones. 
The one article that was located conducted nine 
focus groups; four with VDOT patients (n=8) 
and two with providers (n=14) in San Diego, CA 
and one focus group with patients (n=8) and two 
with providers (n=33) in Tijuana, B.C., Mexico. 
The study participants were accepting of the 
technology and conveyed that they found it to be 
less burdensome and more confidential when 
compared to in-person DOT.  Culture played a 
role as the United States patients valued the 
greater autonomy that VDOT provided and 
Mexican patients valued improved privacy 
(Zúñiga, Collins, Muñoz, Moser, Rangel, 
Cuevas-Mota, Clark, Burgos, & Garfein, 2015). 
 
Terminology 
When conducting this study, discussions took 
place about terminology. There is no term that is 
used consistently and agreed upon. Terms such 
as VDOT, Tele-DOT, mDOT, mobile DOT, 
video-based DOT, remote-DOT, eDOT, and 
others have been used in the literature and 
discussions. In this article, the term VDOT is 
used. VDOT is the name of the technology used 
in the pilot test sites. This is not a product 
endorsement for VDOT.  
 
How VDOT Works and was Used in This 
Study 
The VDOT application used in this study was 
programmed to send the encrypted, time/date 
stamped video to a secure server immediately 
after the participant stopped recording him or 
herself. If the cellular or WiFi connection was 
unavailable, the video remained in the phone’s 
memory, hidden to users, until a signal was 
accessed and the video was sent. To protect 
patient confidentiality, videos were stored on the 
phone in a manner so that the videos could not 
be opened on the phone. Once the server 
received the video, an authenticated message 
was sent back to the phone that caused the video 
to be deleted from the phone.  
 
Staff at the public health agency monitored 
videos as they arrived using a password 
protected website called the Case Management 
System. The HCWs observed videos each 
business day, documented each medication dose 
that was taken as shown in the video, and 
received a daily report listing the identification 
numbers of participants who did and did not 
send videos.  
 
In this study, UCSD pilot tested VDOT in five 
urban and rural counties in California with a 
high incidence of TB. Following treatment 
schedules prescribed by the patient’s care 
provider, participants (patients with TB) were 
either loaned a smartphone from UCSD with 
service or they used their own smartphone. 
Participants were taught how to use the VDOT 
recording application and how the medication 
should be taken and given a brochure containing 
VDOT instructions as a reference. After 
training, participants were asked to take the first 
medication dose using VDOT with the HCW 
present to ensure they knew how to record their 
videos. All remaining doses were taken and 
recorded at a place of the participant’s choosing. 
Participants with missing videos were contacted 
by the HCW to determine whether the 
medication was taken and to troubleshoot 
potential problems the participant may have 
experienced. Clinic staff were informed 
whenever participants missed a medication dose 
so that the clinic staff could proceed with 
contacting the participant according to the 
agency’s standard treatment protocols. 
 
Methods 
 
Interviews and a survey were used to address to 
goal of the study. The study was approved by 
the Public Health Institute Institutional Review 
Board and the University of California San 
Diego Institutional Review Board.  
 
Procedures 
Interviews were conducted with staff at the pilot 
sites and a survey was conducted with users and 
non-users of VDOT at a TB conference in 
California. Non-users were included in the study 
to assess the perceptions of non-users, which 
could be barriers to utilization, and to assess if 
non-user’s perceptions were different than the 
experiences of users. 
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Participants 
Seven staff at the pilot sites were interviewed. 
Eight were invited; one did not respond to the 
request. The inclusion criteria were that the 
person had to work with VDOT at one of the 
five pilot sites. The researchers wanted at least 
one person from each site to participate and for 
people with different roles to participate. We 
interviewed three TB Controllers, two Program 
Managers, one VDOT Coordinator, and one 
billing specialist. All of the interviewees were 
females and worked in public health agencies; 
two worked in rural facilities, and three were 
pre-implementation interviews.  
 
The survey was completed by 56 participants; 
one of them was a remote attendee who emailed 
the completed survey as an attachment. The 
majority of participants were clinicians (86.3%, 
n=44) and most were employed at a public 
health agency (96.1%, n=49). 
 
Interviews 
CCHP worked with the UCSD pilot sites and 
conducted seven interviews with people at the 
five sites.  The pilot sites were county health 
departments in San Francisco, Santa Clara, San 
Joaquin, Imperial, and San Diego. Two of the 
sites were using VDOT for less than two months 
while the others had been using it for years. The 
sample was a convenience sample. 
 
HCWs at the pilot sites were asked to participate 
in a 30-minute recorded interview. The selection 
process was based on who could participate 
(everyone who was asked participated except for 
one person being non-responsive to the email 
request) and their role in the organization. One 
person from each pilot site participated, and they 
had different roles in the VDOT project. Three 
people from San Francisco were interviewed. 
The interviewer guide was developed by CCHP 
staff and reviewed by the collaborating UCSD 
research team. Conference calls were held with 
both organizations until no more changes were 
needed to the interview guide. 
 
The Principal Investigator of the UCSD study, 
Dr. Richard Garfein, introduced the CCHP 
interviewer to the pilot site staff member via 
email. The interviewer explained the interview 
to the potential participant. The participants 
were asked to sign a consent form, which also 
requested that consent be given for the interview 
to be recorded. All participants consented to 
being interviewed and having them be recorded. 
Two researchers from CCHP participated in the 
interviews and one took notes.  
 
Survey 
The purpose of the survey was to assess the 
acceptance levels and experiences with VDOT, 
perceived or experienced benefits and concerns 
of using VDOT, and to collect ideas for other 
applications of VDOT. A survey was developed 
by CCHP in collaboration with UCSD. After 
conducting an extensive literature review, three 
researchers at CCHP developed a draft survey. 
The draft was reviewed and discussed with 
researchers at UCSD. Several iterations occurred 
and after no more changes were identified, the 
survey was reviewed by two people who work in 
county TB control sites. Final revisions were 
made after a conference call with the TB 
professionals at county offices in California. 
Paper versions of the survey were distributed at 
the California Tuberculosis Control Association 
(CTCA) annual meeting held in Sacramento, CA 
on April 20th and 21st 2015. The survey also was 
available to remote conference attendees (people 
could attend all or any part of the conference 
remotely) who could complete the survey and 
send it to one of the researchers or complete it 
online. The survey was distributed to conference 
attendees at the end of the 45-minute 
presentation on VDOT. The presentation was 
given by Dr. Richard Garfein. Attendees were 
asked to complete the survey and return it to the 
CCHP exhibit table. When attendees dropped 
off the completed survey they were entered in a 
raffle for a free Kindle reader.  
 
Analysis 
The recordings from the interviews were 
transcribed and analyzed using ATLAS.ti 
version 6.   Two people coded the transcripts 
independently and the codes were compared. No 
major differences were identified.  
 
The survey data was analyzed using descriptive 
statistics. Graphs and tables were used in the 
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analysis. The data for A-VDOT users and S-
VDOT users were compared as well as for users 
and non-users of both A-VDOT and S-VDOT. 
The former was done to compare the outcomes 
of the two approaches and the latter analysis was 
conducted to determine of perceptions of VDOT 
usage differ from those who have used the 
technology. 
 
Results 
 
Users and non-users of VDOT were included in 
the study. All of the interviewees were VDOT 
users and the survey respondents were 
professionals working in TB, some of which 
were pilot study participants but not all. 
 
Interview Results 
The interviewees all stated that A-VDOT and S-
VDOT each have their pros and cons. For 
example, S-VDOT has the daily interaction and 
A-VDOT has the benefit of observation on 
weekends, holidays, and when the patient is 
travelling. The best approach is to identify what 
works for the patient and to have a ‘menu’ of 
options and for providers to determine, with the 
patient, what is the right method for that patient; 
maybe the method will change at different points 
in treatment. 
 
In terms of barriers, comments centered 
primarily around reimbursement and that private 
insurance does not pay for VDOT (they do not 
pay for in-person DOT, either). Medi-Cal pays 
for in-person DOT but not VDOT. This was a 
major concern as public health departments have 
reduced reimbursement when using VDOT. 
Other challenges were equipment and 
connectivity issues, monitoring side effects, and 
HCWs initially being concerned about losing 
their jobs. For the last item, once it was 
explained that their jobs would not be eliminated 
the concern was minimized.  With regard to 
connectivity issues, the videos in VDOT are 
stored in the phone until connectivity occurs. A 
HCW reported that it is problematic when the 
person has a lapse in connectivity and when he 
or she obtains a connection that numerous 
videos are received by the HCWs 
simultaneously. Another interviewee shared that 
rural regions have connectivity problems. On the 
positive note, interviewees shared their 
expectation that connectivity will improve in the 
future. Lost videos are a problem as HCWs do 
not know if the patient did take his or her 
medication or not. Another challenge that was 
mentioned is that some patients miss the human 
connectivity as relationships between the TB 
staff and patients often form. Except for 
reimbursement, participants indicated that all of 
these issues were not seen as major problems. 
 
The benefits shared included flexibility, patient 
satisfaction, cost effectiveness, and monitoring 
on the weekends and when the patient travels. 
One person mentioned that she works in a small 
clinic and VDOT helps reduce clinic crowding. 
In a large rural county, there is only one DOT 
worker who must cover the entire region. With 
VDOT, there is less travel for the staff, which is 
cost effective. When patients travel, during 
holidays and on weekends, in-person DOT 
cannot be done. A-VDOT allows for patient 
monitoring during these times.  Border-counties 
found VDOT useful as some patients may go to 
Mexico for extended periods of time making 
monitoring and continuity of care impossible.  
 
When asked about eligibility requirements for 
patients to be able to use VDOT, the common 
philosophy was that all patients should be 
considered eligible. Some of the comments that 
were shared is that if the patient is medically 
stable, has successfully completed two weeks of 
in-person DOT, and that the patient is willing 
and can be trusted then the patient should be 
considered eligible. Concerns about language 
translation were shared. One clinic staff person 
mentioned that they have translation services for 
phone but not for webcam, therefore non-native 
English speakers were automatically disqualified 
from using VDOT. If patients have a disability 
or mental health issue that prohibits them from 
being able to use the phone then they should not 
use VDOT.  
 
Interviewees were asked about other 
applications of VDOT. The responses included 
HIV, Hepatitis C, diabetes, individuals on 
psychiatric medications, people with drug 
addiction problems, and the elderly who are on 
multiple medications. One final issue that arose 
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from the interviews was the inquiry about how 
long agencies need to store the videos. Are the 
requirements the same as for other medical 
records? 
 
Survey Results 
Fifty-six people completed the survey. The same 
questions were asked about S-VDOT and A-
VDOT so that the methods could be compared.  
To identify the highest and lowest concerns and 
to make the comparison of A-VDOT and S-
VDOT perceived and experienced concerns and 
benefits, the four options (no concern, minimal 
concern, moderate concern, and major concern) 
were collapsed into two categories (no concern 
or minimal concern; moderate or major concern) 
and the same process was done for the benefits. 
The VDOT types were then compared side-by-
side (see Tables 2 and 3).  
 
Table 2. 
 
Differences in Perceived or Experienced Concerns Between A-VDOT and S-VDOT 
 Asynchronous Synchronous 
  No Concern or 
Minimal Concern 
Moderate 
or Major 
Concern 
No Concern or 
Minimal 
Concern 
Moderate 
or Major 
Concern 
HIPAA compliance/security 43% (n=22) 57% (n=29) 40% (n=20) 60% (n=30) 
Reimbursement 26% (n=13) 74% (n=37) 39% (n=19) 61% (n=30) 
Staff acceptance 70% (n=37) 30% (n=16) 76% (n=38) 24% (n=12) 
Patient’s ability to perform VDOT 55% (n=29) 45% (n=24) 65% (n=33) 35% (n=18) 
Patient’s concerns about confidentiality 55% (n=29) 45% (n=24) 59% (n=30) 41% (n=21) 
Medication adherence 62% (n=32) 38%(n=20) 75% (n=38) 25% (n=13) 
Managing side effects 41% (n=21) 59% (n=30) 50% (n=25) 50% (n=25) 
Connectivity problems 33% (n=17) 67% (n=34) 29% (n=14) 71% (n=35) 
Equipment problems 35% (n=18) 65% (n=33) 40% (n=20) 60% (n=30) 
Workload increases 87% (n=45) 13% (n=7) 92% (n=46) 8% (n=4) 
Staff layoffs 82% (n=41) 18% (n=9) 79% (n=37) 21% (n=10) 
Training staff 63% (n=33) 37% (n=19) 75% (n=38) 25% (n=13) 
Training patients 55% (n=29) 45%(n=24) 53% (n=27) 47% (n=24) 
Start-up costs 35% (n=18) 65% (n=33) 41% (n=20) 59% (n=29) 
Legal issues 38% (n=19) 62% (n=31) 45% (n=21) 55% (n=26) 
Lack of data on the efficacy of VDOT 74% (n=39) 26% (n=14) 76% (n=38) 24% (n=12) 
 
Discussion 
 
Overall, there is a strong interest in using VDOT 
and there are numerous benefits, some concerns, 
and potential other applications.  
 
Utilization 
VDOT is used in about 25 percent of TB control 
county agencies that participated in the survey. 
Synchronous is used more than asynchronous; 
about a quarter of users use both modalities. It is 
recommended that in-person DOT, A-VDOT, 
and S-VDOT all be available so that the method 
that best matches the needs to the patient can be 
used. There is a high interest in using or 
expanding VDOT use. 
 
Benefits 
VDOT eliminates or reduces travel time and 
costs for both the public health agency and the 
patient. VDOT also reduces crowding in small 
clinics. Flexibility is another benefit as when 
using A-VDOT no set appointment time is 
needed. A-VDOT allows for observation of 
medication ingestion during weekends and 
holidays, when HCWs typically do not work. 
VDOT allows for observation when a patient is 
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Table 3. 
 
Differences in Perceived or Experienced Benefits between A-VDOT and S-VDOT 
 
travelling or when he/she lives in more than one 
state or country. There is increased safety and 
reduced exposure to TB for the HCW as the 
worker does not need to travel, be in unsafe 
areas, and be in direct contact with the patients. 
 
Concerns 
In California, Medi-Cal reimburses for in-person 
DOT is reimbursed but not VDOT. Managing 
side effects is a concern. It was reported that 
side effects are more easily managed using S-
VDOT than A-VDOT. If a patient on A-VDOT 
is having side effects, switching the person to S-
VDOT is recommended. Connectivity problems, 
especially in rural areas, and start-up costs are 
problematic. 
 
 
Other Uses of VDOT 
For other applications of VDOT, HIV patients 
on antiretroviral therapy, Hepatitis C and many 
other applications were identified. Psychiatric 
illnesses, such as bipolar disorder, may be easier 
to manage with VDOT, as these patients often 
stop taking their medications when they are 
feeling better. 
 
Even with its potential, VDOT is not appropriate 
for all patients. Patients with disabilities or 
language barriers, for example, may not be good 
candidates for VDOT. The situation should drive 
what modality is used.  That is why when using 
VDOT, having both A-VDOT and S-VDOT 
available for patients is recommended. This  
 
 
allows the HCW and patient to select the best 
modality for the circumstances.  
 
When benefits and concerns of users and non-
users were compared by percentage of responses 
(data not shown), concerns generally declined 
and the benefits were greater than expected for 
all categories. There are two areas of concern 
that increased (patient’s concern about 
confidentiality, medication adherence, but the 
increased was minimal (2 percent or less). This 
indicates that VDOT users experienced fewer 
concerns and greater benefits than non-users. 
This implies that perceived barriers to using 
VDOT are lower than user’s experiences and the 
benefits are greater than anticipated.  
 
While VDOT has been shown to have a positive 
impact on TB treatment, there are unique 
challenges to using VDOT in place of in-person 
DOT, such as difficulties with the 
equipment/connectivity and reimbursement 
differences. These challenges may be solved by 
establishing clear protocols for utilizing VDOT, 
technological improvements, and reimbursement 
policy changes. While these challenges do exist, 
the benefits appear to outweigh these noted 
challenges.  
 
The expansion in utilization of VDOT is 
recommended. To successfully achieve this 
outcome, the following activities are needed: 
• changes in policies so that VDOT is a 
reimbursable service, 
 
Asynchronous Synchronous 
  No Benefit or 
Minimal Benefit 
Moderate or 
Major Benefit 
No Concern or 
Minimal 
Benefit 
Moderate or 
Major Benefit 
Cost effectiveness 6% (n=3) 94% (n=44) 2% (n=1) 98% (n=45) 
Patient satisfaction 7% (n=3) 93% (n=38) 4% (n=2) 96% (n=47) 
Staff satisfaction 6% (n=3) 94% (n=44) 6% (n=3) 94% (n=45) 
Staff safety 12% (n=6) 88% (n=43) 15% (n=7) 85% (n=41) 
Improved medication adherence 19% (n=9) 81% (n=38) 20% (n=9) 80% (n=37) 
Managing side effects 68% (n=32) 32% (n=15) 46% (n=21) 54% (n=25) 
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• research that compares the VDOT 
technologies and identifies the key 
features of the technologies that address 
the identified concerns including the 
cultural barriers to utilization (e.g., 
translation services), 
• educate TB providers about VDOT to 
reduce the gap between perceived and 
actual benefits and problems related to 
using VDOT, 
• explore the option of a having a central 
hub where VDOT videos are reviewed 
and monitored, and 
• perform research on using this 
technology with other health problems, 
such as HIV. 
 
A limitation of this study is that the number of 
interviewees was small (n=7) and all were 
female. Another limitation was the small 
convenience sample used in the survey. It is 
possible that counties with low incident rates 
were not included as they did not see attendance 
at the CTCA conference as a priority due to the 
low number of cases. Therefore, low-incident 
counties may not be represented in the survey 
results. Because the survey respondents were 
CTCA attendees, the findings cannot be 
generalized. 
 
Conclusion 
 
This study shows that there is a high interest in 
VDOT and that after people use VDOT their 
concerns diminish and the benefits are higher 
than anticipated. If VDOT becomes a 
reimbursable service and as the technology 
improves, the barriers to utilization will decrease 
and the full benefits can be achieved. 
 
VDOT has been shown to be a viable method for 
delivery DOT to TB patients. Overall, users of 
VDOT have reported numerous benefits that 
have a positive impact on the staff, patients, and 
the public health department. There is a high 
interest in using this modality and policy 
changes related to reimbursement are needed 
before widespread utilization can occur. There 
are other health issues where VDOT can be 
applied that are worthy of exploration. With the 
improvements in technology and decreased 
funding, VDOT is a viable solution to providing 
DOT to TB patients.  
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